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Abstract: The exposure duration and tissue distribution
will likely dictate the success of vascular endothelial growth
factor (VEGF) in therapeutic angiogenesis. We hypothesized
that these variables can be regulated via the manner in
which the VEGF is incorporated into polymer constructs
(formed with a gas foaming technique) used for its delivery.
VEGF was incorporated directly into poly(lactide-co-glycol-
ide) (PLG) scaffolds or pre-encapsulated in PLG micro-
spheres used to fabricate scaffolds. Protein release kinetics
and tissue distribution were determined using iodinated
VEGF. VEGF was positioned predominantly adjacent to
scaffold pores when incorporated directly and was released
rapidly (40–60% in 5 days). Pre-encapsulation led to the
VEGF being more deeply embedded and resulted in a de-
layed release. Alterations in polymer composition, scaffold
size, and matrix composition generated minor variations in
release kinetics. In vivo, the released VEGF generated local
protein concentrations above 10 ng/mL at distances up to 2
cm from the implant site for the 21 days of the experiment,
with negligible release into the systemic circulation, and
significantly enhanced local angiogenesis. These data indi-
cate that VEGF can be administered in a sustained and
localized fashion in vivo, and the timing of VEGF delivery
can be altered with the mechanism of incorporation into
polymer scaffolds used for its delivery. © 2006 Wiley Peri-
odicals, Inc. J Biomed Mater Res 79A: 176–184, 2006
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INTRODUCTION
Coronary heart disease (CHD) is the leading single
cause of death among Americans, and significant at-
tention has turned toward the development of new
therapies for the millions of patients diagnosed with
this disease. Standard treatment of CHD often in-
cludes lifestyle changes (i.e., weight and stress reduc-
tion, nutrition, exercise, eliminate smoking) and vari-
ous medications. Patients suffering with more severe
cases require the invasive mechanical procedures of
angioplasty or bypass surgery to restore perfusion in
the diseased areas. However, many patients are not
viable candidates for these procedures because of age
and the presence of other diseases (i.e., diabetes, obe-
sity, and hypertension). For those who undergo these
surgical treatments, a high percentage suffer from re-
stenosis while for others revascularization is insuffi-
cient.1 New therapies may eventually allow one to
conquer this disease. Therapeutic angiogenesis, the
promotion of neovascularization to restore adequate
perfusion in ischemic regions, offers enormous prom-
ise for individuals suffering from CHD.
Angiogenesis is the development of nascent blood
vessels via sprouting from the sides and ends of pre-
existing vessels or by intussusception, longitudinal
division of existing vessels with periendothelial cells.2
This normal, physiologic process occurs during events
such as embryonic development, wound healing, in-
flammation, and female reproduction. The major
stages of angiogenesis entail the activation, migration,
and proliferation of endothelial cells (EC) (the cells
that form the lining of blood vessels), the assembly of
these cells into tube-like structures forming immature
vessels, the stabilization of these vessels through EC
association with mural cells (pericytes and smooth
muscle cells), and deposition of extracellular matrix
around the maturing blood vessels.3,4
Angiogenesis is a complex, multistage cascade of
events involving numerous proteases, cytokines, cell
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types, and growth factors, all functioning in a con-
certed manner. One of the most widely studied regu-
lators of this process is vascular endothelial growth
factor (VEGF).5 This 46-kDa dimeric glycoprotein is a
known mitogen of ECs. VEGF initiates EC migration
and proliferation during angiogenesis, causing imma-
ture tube-like structures to branch from mature blood
vessels. If this signal is removed, these nascent vessels
regress. Additionally, VEGF, once introduced into a
host environment, has a half-life of 90 min.6 In order to
provide tissues with adequate exposure to VEGF to
elicit a cellular response, a constant supply of the
soluble signal is most likely required. However, owing
to the potent mitogenic nature of VEGF, systemic ex-
posure may promote undesired vascularization in
nontarget sites as well as enhance pathological condi-
tions (i.e., tumor growth, retinopathies) in distant ar-
eas. Thus, for therapeutic purposes, the presence of
VEGF must not only be sustained, but also be local-
ized to the ischemic tissue region.
In this report, we focus on developing a polymeric
system capable of controlling the kinetics of VEGF
release as well as demonstrating that such an ap-
proach can allow for sustained and localized presence
of the protein in vivo. In previous investigations, a
poly(lactide-co-glycolide) (PLG) system was devel-
oped that allowed a sustained delivery of biologically
active VEGF in vitro while greatly enhancing neovas-
cularization in vivo.7–9 Based on these studies, we hy-
pothesize that varying the approach of VEGF incorpo-
ration into the PLG scaffold will enable us to control
how the protein is distributed in the matrix and, thus,
how it is released. Furthermore, we investigate
whether this strategy provides the capability to release
VEGF in a manner that creates a local concentration
that could attract blood vessels in surrounding tissue
without having significant systemic exposure to the
protein.
MATERIALS AND METHODS
PLG was purchased from either Medisorb-Alkermes
(Cambridge, MA; 85:15) or Boehringer Ingelheim [Peters-
burg, VA, 75:25 Resomer RG752 (intrinsic viscosity  0.24
dL/g, MW  16 kDa), Resomer RG755 (intrinsic viscosity 
0.59 dL/g, MW  63 kDa), Resomer RG756 (intrinsic vis-
cosity  0.80 dL/g, MW  98 kDa), and 50:50 Resomer
RG502 (intrinsic viscosity  0.20 dL/g)]. Iodinated VEGF
(125I VEGF, specific activity  3500–4600 Ci/mmol) was
obtained from Perkin Elmer (Boston, MA). CB17 SCID mice
were procured from Taconic Farms Inc. (Germantown, NY)
and C57Bl/6J mice from Jackson Laboratories (Bar Harbor,
Maine). Bovine serum albumin conjugates, Alexa Fluor 488
and Texas Red, were purchased from Molecular Probes (Eu-
gene, OR) and Collagenase Type II was bought from Worth-
ington Biochemical Corporation (Lakewood, NJ). Other sup-
plies were obtained from Sigma (St. Louis, MO), unless
noted otherwise.
Microspheres and scaffold preparation
A variety of PLGs, differing in composition (lactide to
glycolide ratio) and molecular weight, were used to prepare
microspheres (particle size, 5–50 m), incorporating growth
factor, using a double emulsion (water/oil/water) process
as previously described.10 An aqueous growth factor solu-
tion was mixed with PLG dissolved in ethyl acetate to form
the first emulsion. A 1% (w/v) solution of poly(vinyl) alco-
hol (PVA) in ethyl acetate was combined with the first
emulsion, vortexed, and added to a stirring solution of 7%
(w/v) ethyl acetate, 3% (w/v) PVA, and water. The ethyl
acetate in solution evaporated during the 3-h stir period, and
the microspheres were collected by filtration and lyophi-
lized.
Scaffolds were prepared from particulate PLG and PLG
microspheres using a gas foaming/particulate leaching pro-
cess, as previously described.11,12 Scaffolds were fabricated
from either a mix of particulate PLG (85:15, ground to an
average diameter of 125 m, 125I VEGF, 0.2 Ci) and up to
30% of total polymer mass of PLG microspheres (125I
VEGF, 0.2 Ci) or fabricated entirely from microspheres
(125I VEGF, 0.2 Ci). In either case, the polymer in the form
of particles, microspheres, or a mixture of both was com-
bined with NaCl particles (diameter, 250–425 m) and 1%
(w/v) alginate solution. The alginate serves to increase pro-
tein incorporation and functions as a stabilizer.7 This mix-
ture was lyophilized and pressed into a pellet using a Carver
press. The scaffolds were placed under high pressure CO2
gas and allowed to equilibrate. The pressure was rapidly
returned to ambient conditions leading to a thermodynamic
instability and causing the polymer, whether in the form of
particulate or microspheres, to foam and create an intercon-
nected structure around the NaCl. Both types of particles
foam and fuse together to create the scaffold, and no distinct
particles or microspheres are present in the scaffold after this
processing. The NaCl was leached in a CaCl2 solution to
create a macroporous structure.13 Scaffolds were 13 mm in
diameter and 3 mm thick (40 mg total polymer and 760 mg
NaCl) or 4.7 mm in diameter and 1.5 mm thick (3 mg total
polymer and 50 mg NaCl).
In vitro protein release
125I VEGF was incorporated into the scaffolds as a tracer,
and scaffolds (n  4–8) were placed in phosphate buffer
saline (PBS) containing calcium and magnesium, and incu-
bated at 37°C. At set time points, a sample of the buffer was
removed and analyzed using a Packard  counter. The re-
maining liquid was removed and discarded, and a fresh
aliquot of PBS was added to the scaffold. The quantity of
protein released from the scaffold was determined by com-
paring it to the total quantity of radioactivity initially
present in each sample.
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Confocal microscopy imaging of protein
distribution
Microspheres (encapsulating BSA conjugated fluorophor,
Texas Red) were prepared from 75:25 PLG (MW  63 kDa)
and added to a combination of 85:15 PLG particles, the BSA
conjugated fluorophor Alexa Fluor 488, and alginate, to
fabricate scaffolds using the gas foaming/particulate leach-
ing method described earlier. Scaffolds were analyzed using
a BioRad confocal microscope (Hercules, CA) and a dual
channel filter. A series of images (z-stack), 4–8 m apart in
depth, were taken of several areas of scaffolds, totaling 100
m in depth for each area. Images of the scaffold surface, as
well as the interior, were examined.
In vivo protein release
Mice (n  5 per time point) were anesthetized with a
mixture of ketamine and xylazine. A small incision was
made on the dorsal side of the rodent, and a single scaffold
was subcutaneously implanted into the pocket. Prior to im-
plantation, each scaffold was submerged in 100% ethanol for
15 min. This sterilization technique did not significantly
influence the bioactivity of the protein incorporated and
released from the scaffolds, as previously determined in EC
proliferation assays8,9 with this system. After removing the
ethanol, the scaffolds were rinsed five times (5 min/rinse)
using sterile PBS. The scaffolds were implanted into SCID
mice to monitor VEGF release when directly incorporated
and, for all other studies, C57Bl/6J mice were used. At
designated time points, scaffolds were retrieved and placed
in a dispase (2.4 Units/mL)/collagenase (200 Units/mL)
solution to digest any tissue attached to the implant. Scaf-
folds were analyzed using the  counter following tissue
digestion to determine the unreleased quantity of 125I VEGF
remaining in the scaffold. The dissolved tissue was also
analyzed to quantify 125I VEGF in the tissue that had infil-
trated the implants. Tissue sections were obtained at various
distances from the implant site, along with blood and liver
samples. These tissues were analyzed for the presence of 125I
VEGF using the  counter. Quantities of 125I VEGF were
converted to VEGF concentrations (ng/mL) using the
known specific activity of the tracer and the weighed masses
of the tissue samples (assuming tissue density of 1.0 g/mL).
For all scaffolds, 3 g of protein were incorporated. NIH
guidelines for the care and use of laboratory animals (NIH
publication No. 85–23, revised in 1985) have been observed.
Vessel formation
Scaffolds containing no growth factor and scaffolds di-
rectly incorporating 3 g of VEGF were prepared as de-
scribed earlier and subcutaneously implanted in C57Bl/6J
mice (n  3, per animal per condition), as previously de-
scribed.7–9 Scaffolds were retrieved from subcutaneous
pockets after 2 weeks, fixed in formalin, and stored in eth-
anol. Tissues were subsequently embedded in paraffin, sec-
tioned (5 m thick), and sections were placed on glass
slides at the histology core in the School of Dentistry at the
University of Michigan. The sections were stained for CD31
(antigen found on ECs) at the University of Michigan Cancer
Center Histology Core, to identify blood vessels, as previ-
ously described.7–9 The density of blood vessels was deter-
mined as previously described.7–9 In brief, CD31-stained
sections were viewed at 200 magnification using a light
microscope (Nikon; Indianapolis, Indiana). Blood vessels in
three different tissue samples from each condition (n  3 per
condition) were manually counted. The matrix area was
determined using Image Pro Plus software to calculate the
blood vessel density from the number and area measure-
ments.
Statistical analysis
Student t-tests were performed on the raw data of the
release studies and in vivo angiogenesis study. For the stud-
ies quantifying VEGF presence in the blood and liver, the
statistical difference of these measured values from zero was
determined.
RESULTS
Protein distribution in polymer scaffold
Both types of particles—used to fabricate the scaf-
folds (microspheres and particulate PLG)—foamed
and fused together to create physically continuous
structures in which neither distinct microspheres nor
particulate PLG could be distinguished, as previously
reported.7–9 The distribution of protein incorporated
into scaffolds with both methods, direct versus pre-
encapsulation into microspheres used to form the scaf-
folds, was assessed using protein labeled with two
different fluorophores and confocal microscopy. Di-
rect incorporation of protein into scaffolds resulted in
an even distribution of protein throughout the scaf-
folds, and a localization predominantly near the sur-
face, as evidenced by a high concentration of the pro-
tein adjacent to the pores in the scaffolds (Fig. 1). In
contrast, pre-encapsulation of protein into the micro-
spheres used in the foaming process to fabricate scaf-
folds resulted in a more discrete localization, and the
protein was more deeply embedded in the scaffold
(Fig. 1).
In vitro release kinetics
The release kinetics for protein incorporated with
both methods was subsequently analyzed using 125I
VEGF. Protein incorporated directly was released with
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an initial rapid rate for the first 3–5 days, followed by
a slower release rate for the remainder of the experi-
ment duration. Protein release was sustained for more
than 21 days. As the percentage of polymer in the form
of microspheres used to prepare the scaffolds in-
creased, the burst release (amount released in the first
24 h) increased from (25  3)% (all 85:15 particles) to
(54  3)% (all microspheres) (Fig. 2).
The release kinetics of protein pre-encapsulated into
microspheres before forming into scaffolds was next
assessed to determine whether this approach would
allow for a delayed release and to assess whether this
release could be regulated by the PLG composition
(lactide to glycolide ratio and molecular weight). 125I
VEGF was incorporated into microspheres of 85:15,
75:25, or 50:50 PLG. Scaffold protein release kinetics
were similar from pre-encapsulation into micro-
spheres of 85:15 and any of the low molecular weight
75:25 PLG. However, when delivering protein from
microspheres made from 50:50 PLG, the release rate
was slightly greater for the burst portion of the profile
and faster during the sustained portion relative to the
other two polymer compositions [Fig. 3(A)]. The effect
of PLG molecular weight on the release kinetics was
determined using 75:25 PLG, ranging from 16 to 98
kDa. The burst portion of the release profiles was
similar for all three molecular weights, and only a
slight difference was noted in the slopes of the sus-
tained release rates [Fig. 3(B)]. However, the release
rate of protein pre-encapsulated in PLG microspheres
was, in all conditions, slower than that of the protein
directly incorporated into scaffolds [compare Figs.
3(A,B) to Fig. 2].
The effects of several processing parameters on re-
lease kinetics when the protein was pre-encapsulated
in microspheres were also analyzed. Specifically, the
effects of polymer concentration in the fabrication of
microspheres, the scaffold size, and the construction
of the scaffold using all microspheres or a combination
of microspheres and polymer particles, were ana-
lyzed. Increasing the PLG concentration in the micro-
sphere preparation process from 5 to 30% halved the
protein released during the burst from 11 to 5% (Fig.
4). However, the protein incorporation efficiency in
the microspheres was decreased from (36  5)% to
(11  0.4)%. Scaffolds of differing dimensions were
prepared from the polymer in the form of all micro-
spheres as well as from a combination of microspheres
and 85:15 particulate. The protein release kinetics for
the scaffolds formed entirely from microspheres with
protein pre-encapsulated in 50:50 and 75:25 (16 and 63
kDa) PLG during the burst were only weakly affected
by scaffold size, with smaller scaffolds yielding
slightly faster release kinetics as the lactide concentra-
tion and molecular weight increased. In contrast, no
differences were noted in the sustained release period.
Figure 1. Confocal microscopy image of interior surface of
scaffold formed with proteins containing either conjugated
Alexa Fluor 488 using the direct incorporation method (po-
sitioned predominantly adjacent to pores), or Texas Red
formed by pre-encapsulating the protein in 75:25 (MW 63
kDa) microspheres (embedded deeper in the matrix). Ar-
rows denote open pores. Original magnification 200. Note:
Alexa Fluor 488 (green fluorescence) and Texas Red (red
fluorescence). [Color figure can be viewed in the online
issue, which is available at www.interscience.wiley.com.]
Figure 2. Release profiles of VEGF directly incorporated
into scaffolds fabricated from all microspheres (open cir-
cles), a combination of 85:15 PLG particles and either 30%
(solid triangles) or 20% (solid squares) microspheres, or all
85:15 particles (solid circles). Data represent average values
(n  4–8), and error bars indicate standard deviation, except
for scaffolds with 20% microspheres in which error bars
represent standard error of the mean. The differences in
release values for scaffolds formed with all microspheres or
30% microspheres, as compared to all other conditions, were
statistically significant (p  0.05) at all time points. The
differences between the scaffolds fabricated with 20% mi-
crospheres and scaffolds formed with no microspheres were
not statistically significant (p  0.05), except at day 2 and 5.
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Scaffolds fabricated entirely from 75:25 (MW 98 kDa)
or 85:15 PLG microspheres demonstrated faster re-
lease rates during both the burst and the sustained
portion of protein delivery (Table I). Finally, varying
the ratios of microspheres versus particulate poly-
mer—used to fabricate scaffolds—resulted in little ef-
fect on the burst release. The only exception was with
75:25 (MW 16 kDa) PLG, in which the scaffolds
formed entirely from microspheres had a slightly
higher burst release (Table I). During the sustained
delivery period, using a mixture of microspheres and
particulate—to form scaffolds—resulted in a slower
protein release rate. The only exception was when
85:15 PLG was used to form microspheres, as no dif-
ference was evident in this condition (Table I).
Protein release and localization in vivo
VEGF release kinetics and subsequent distribution
throughout the surrounding tissues were next ana-
lyzed following scaffold implantation into the subcu-
taneous tissue of mice to determine how the release
kinetics observed in vitro related to in vivo release.
Figure 3. Effects of polymer composition and molecular
weight on release of VEGF pre-encapsulated in microspheres.
(A) Pre-encapsulated protein release from scaffolds formed
from 85:15 PLG particles and microspheres fabricated using
50:50 PLG (solid squares), 75:25 (solid triangles), and 85:15
(solid circles). * denotes that differences in values from 50:50
PLG scaffolds, as compared to the other two conditions, were
statistically significant (p  0.0001) after day 3. No statistically
significant differences in values between the 75:25 and 85:15
PLG conditions were noted (p  0.05) at any time point. (B)
Protein release rates from matrices formed with various 75:25
PLG [MW  16 kDa (solid squares), 63 kDa (solid triangles), 98
kDa (solid circles)] microspheres. The differences between the
values at each condition, as compared to the other conditions,
were generally not statistically significant. The only exceptions
were at day 7 (*), where p  0.01 between all conditions, and at
day 21 (*) for 16 and 63 kDa relative to 98 kDa 75:25 PLG (p 
0.05). Data represent average values (n  4–8), and error bars
indicate standard deviation.
Figure 4. VEGF release from scaffolds prepared with 85:15
particulate PLG and protein pre-encapsulated in 75:25
(MW  63 kDa) PLG microspheres. The concentration of
polymer in the microscope preparation process was varied
from 5% (solid squares) to 15% (solid triangles), and 30%
(solid circles). Data represent average values (n  4–8), and
error bars indicate standard deviation. The differences in
values between conditions were not statistically significant,
with the exception of day 7 (*), at which the difference
between each of the conditions compared to the others was
significant (p  0.015).
TABLE I
VEGF Released in the First 24 h (Burst) and the
Subsequent Release Rate from Scaffolds Prepared from






Smalla scaffolds (all microspheres)
50:50 35 0.7
75:25 (16 kDa) 37 0.7
75:25 (63 kDa) 32 0.8
75:25 (98 kDa) 24 1.3
85:15 20 0.7
Largeb scaffolds (all microspheres)
50:50 22 0.8
75:25 (16 kDa) 24 0.8
75:25 (63 kDa) 17 0.9




75:25 (16 kDa) 11 0.5
75:25 (63 kDa) 11 0.4
75:25 (98 kDa) 9 0.5
85:15 12 0.4
aSmall: 4.7  3 mm2 scaffolds.
bLarge: 13  3 mm2 scaffolds.
cMixture: 85:15 particles 	 microspheres.
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Scaffolds were removed at various time points, and
the 125I VEGF remaining in the polymer was quanti-
fied to determine the release kinetics of VEGF. Direct
incorporation led to an initial burst release of 60% of
the total incorporated protein within the first 24 h,
slightly greater than that observed in vitro, followed
by a sustained release of 0.6% per day. VEGF pre-
encapsulated in microspheres prior to scaffold fabri-
cation led to a lower burst release (27% of incorpo-
rated VEGF), followed by a greater release rate (1.8%
per day) than those observed with VEGF directly in-
corporated into scaffolds (Fig. 5). The rate of protein
release was greater in vivo in both the burst and sub-
sequent release phases, as compared to that measured
in vitro.
The distribution of VEGF released from the scaf-
folds was subsequently analyzed to determine
whether a localized delivery was achieved with this
system. Both the tissue that had grown into the scaf-
folds and surrounding tissues, along with the internal
organs, were analyzed. At 24 h following implanta-
tion, a high VEGF concentration was found within the
tissue growing into the scaffolds, and the VEGF con-
centration rapidly declined with distance from the
scaffold (Fig. 6). The VEGF concentration within the
tissue infiltrating the scaffold and in the surrounding
tissues decreased at day 5 and further declined at day
21. However, at all time points, the VEGF concentra-
tion in the surrounding tissue was greater than 10
ng/mL. Blood samples drawn from the left ventricle
of the heart showed the presence of trace quantities of
protein (25  33 ng/mL) at day 1, but only baseline
quantities at the other time points [Fig. 7(A)]. Simi-
larly, liver tissue contained very low concentrations of
VEGF at day 1 (10  2 ng/mL), and VEGF was unde-
tectable at all later time points [Fig. 7(B)]. In both
cases, at all time points, the values were not signifi-
cantly different from zero (p  0.05).
New blood vessel formation
The utility of this system to qualitatively and quan-
titatively enhance local angiogenesis was next as-
Figure 5. In vivo VEGF release profiles. VEGF directly in-
corporated into scaffolds (solid squares) or pre-encapsulated
in 75:25 PLG (i.v.  0.59 dL/g, 63 kDa) microspheres (solid
circles). Data represent average values (n  5), and error
bars indicate standard deviation. * denotes significant dif-
ferences (p  0.02) between the values of the two conditions.
Figure 6. VEGF distribution in animal tissue sections
around implant site. VEGF concentration both within the
tissue invading scaffolds (distance  0 cm) and within tissue
sections at various distances from the implant site at day 1
(solid circles), 5 (solid squares), and 21 (solid triangles). Data
represent average values (n  5), and error bars indicate
standard error of the mean. * denotes that the differences in
values between the various time points was statistically
significant (p  0.03) at that distance.
Figure 7. VEGF concentration measured in (A) blood sam-
ples taken from heart and (B) liver tissue measured over a
5-week period. Data represent average values (n  5), and
error bars indicate standard deviation. No values from ei-
ther site at any time were statistically distinct (p  0.05) from
zero.
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sessed. Scaffolds releasing VEGF (direct incorpora-
tion) induced significant growth of microvessels
relative to the control condition, as evidenced by the
much larger density of CD31 positively stained vessels
in histological samples [Fig. 8(A,B)]. The rapid release
and a sustained localized presence of VEGF yielded a
statistically significant increase in vessel density (p 
0.05) [Fig. 8(C)].
DISCUSSION
Directly incorporating VEGF versus pre-encapsulat-
ing the protein prior to incorporation into polymer
scaffolds altered the distribution of VEGF in the scaf-
fold and how the factor was released. Manipulation of
polymer properties and processing parameters, such
as polymer composition, scaffold size, and makeup,
resulted in minor alterations in the release kinetics.
Additionally, the protein release kinetics in vivo were
also controlled by the mechanism of protein incorpo-
ration into scaffolds, and the released VEGF created a
local concentration in tissue sections surrounding the
implanted matrix, with little systemic exposure to the
protein.
The manner of protein incorporation into the poly-
mer matrix determined the distribution of the growth
factor in the scaffold and affected its release. Analysis
of the polymer constructs via confocal microscopy
demonstrated that direct protein incorporation pre-
dominantly positioned the protein adjacent to the
pores, potentially allowing it to diffuse rapidly out of
the matrix. Pre-encapsulation of VEGF into micro-
spheres subsequently used to form scaffolds led to the
protein being more deeply embedded in the polymer,
and this was reflected in the slower release as com-
pared to protein directly incorporated into the matrix.
In all studies investigating pre-encapsulated protein
release, the rate of delivery was significantly slower
than the release demonstrated with direct protein in-
corporation. The protein release rate was sensitive to
certain, but not all polymer properties and processing
parameters that were tested. The ratio of lactide to
glycolide in the PLG affected the release rate of pre-
encapsulated protein. However, weak effects on VEGF
release kinetics were observed with alterations in
polymer molecular weight over the tested range. In
general, smaller scaffolds also had faster protein re-
lease kinetics than did larger counterparts with the
same composition. Altogether, these data suggest that
the method of protein incorporation had the greatest
effect on release kinetics. However, the release kinetics
achieved with the two incorporation techniques could
be fine-tuned through alterations in a variety of poly-
mer properties and processing parameters.
In all studies using pre-encapsulated VEGF in vitro,
Figure 8. Vessel density produced in scaffolds containing no
growth factor and those rapidly releasing VEGF, following 2
weeks of subcutaneous implantation. Photomicrographs of tis-
sue sections from blank scaffolds (A) and VEGF-releasing scaf-
folds (B) following immunohistochemical staining for CD31
(EC marker) (100 magnification). (C) Quantification of vessel
density. Values represent averages and standard deviation,
and * indicates statistically significant difference (p  0.015)
between the two conditions. [Color figure can be viewed in the
online issue, which is available at www.interscience.wiley.com.]
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the initial burst release was followed by an incomplete
release. The burst release from these PLG scaffolds
most likely resulted from the rapid desorption or dif-
fusion of VEGF that associated with the surface of the
microspheres during the fabrication process. The sub-
sequent release most likely resulted from the protein
located deeper within the microspheres that diffused
through the polymer and/or was released as the poly-
mer degraded. This phenomenon has been illustrated
in several studies administering other bioactive fac-
tors14–18 from 50:50 PLG microspheres. One of the
primary sources of the incomplete or halted release
has been attributed to protein instability.19–23 The deg-
radation of the polymer into lactic and glycolic acids
generates an acidic microenvironment in which pro-
teins readily experience hydrolysis (e.g. cleaved Asp-X
linkages) and lose stability.24–26 The hydrolyzed pro-
teins may denature,15 nonspecifically adsorb onto
polymer surfaces, 27,28 and form noncovalent and co-
valent aggregates.29 As the polymer degrades or
erodes, new small pores develop, increasing the sur-
face area available for protein to adsorb.28 Addition-
ally, the acidic microenvironment promotes alter-
ations in the surface and internal morphology of the
polymer, leading to the development of a “skin” layer
on the microsphere surface.30 This skin layer affects
the permeability30 of the polymer and the subsequent
protein release after the burst, leading to the incom-
plete release. Although these previous studies were
conducted on microspheres only, the findings most
likely relate as well to polymer scaffolds prepared
using microspheres. Methods to improve protein sta-
bility in PLG microspheres remain under develop-
ment.31
The PLG scaffolds were successful in delivering
VEGF in vivo with two distinct release kinetics, a rapid
or a delayed release rate. The differences in release
rates noted in vitro versus in vivo may be related to
variations in protein stability in the two environments.
As the polymer degrades, the acidic microenviron-
ment generated in vitro may not exist in vivo because of
the natural removal of waste products by the host and
the maintenance of a physiological pH. In the in vitro
experiments, the released protein may have formed
covalent aggregates29 and have nonspecifically ad-
sorbed onto the surfaces of the matrix,27,28 reducing
the amount of protein measured in the release buffer
and causing incomplete protein release. In vivo, many
endogenous proteins exist that are free to adsorb onto
the surface of the scaffold, perhaps blocking VEGF
association or allowing the released protein to more
fully disengage from the matrix or both. Additionally,
the physical forces that exist in a mechanically dy-
namic setting may have increased the release of
growth factors32 relative to the mechanically static
release environment in vitro. Two mice models, SCID
and C57Bl/6J mice, were used in the in vivo studies.
The use of the SCID mice in the first study investigat-
ing VEGF release following direct incorporation is not
expected to affect the results, as an immune response
requires several days to present, and so the presence
or lack of immune competence in host animals should
only be significant over longer time frames.
The VEGF released from the polymer matrix was
distributed in tissue sections up to 2 cm from the
implant, and these molecules remained localized to
their target area with little systemic exposure, as evi-
denced by the low levels of VEGF detected in samples
of blood and liver tissue. VEGF, once released from
the scaffolds in vivo, is expected to be transiently
present because of its short half-life. Therefore, the
continuous high levels of VEGF in the tissues sur-
rounding the implanted PLG are most likely depen-
dent on continuous VEGF release from the scaffold. In
addition, the very transient systemic VEGF exposure
with this delivery system is unlikely to lead to angio-
genesis at other sites, because of the lack of sustained
VEGF presence anywhere except in the immediate
vicinity of the implanted scaffold. Although the spe-
cific in vivo VEGF concentration required to elicit an
EC response is unknown, the in vitro concentration of
VEGF required to invoke an EC response is 10 ng/
mL.8 The VEGF concentration in tissue samples, re-
sulting from sustained VEGF delivery in this system,
were equal to or greater than this value for the 21-day
duration of the experiment. To perform this calcula-
tion, the density of tissue was assumed to be the same
as water (1.0 g/mL). Previous studies from our
group, with both of these approaches to protein en-
capsulation, have demonstrated the biological activity
of VEGF released from these polymer scaffolds.8,9 Ad-
ditionally, the significant increase in vessel density
demonstrated in these in vivo studies confirms the
bioactivity of the VEGF incorporated and released
from this polymer system.
CONCLUSION
In summary, a PLG system with the ability to ad-
minister proteins in a temporal fashion was developed
using two protein incorporation techniques. The in-
corporation techniques determined the distribution of
the protein in the matrix and the kinetics of release.
Coupling these incorporation methods with several
manipulations of polymer properties and formulation
variables allows one to alter the release. The released
VEGF was present up to 2 cm from the implant and
remained localized to the target area with negligible
release into the systemic circulation. Released VEGF
induced significant vessel formation in the scaffold
tissue, demonstrating biological activity of the re-
leased protein. These results support the concept of
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localized angiogenesis for therapeutic purposes, as
well as the development and understanding of other
processes that require temporal delivery of bioactive
factors.
We thank the NCI Biological Resources branch for gener-
ously providing VEGF used in our studies.
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